Pharmacokinetics of Recombinant Antithrombin III in Neonates Undergoing Extracorporeal Membrane Oxygenation

Trial Profile

Pharmacokinetics of Recombinant Antithrombin III in Neonates Undergoing Extracorporeal Membrane Oxygenation

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 15 Jan 2015

At a glance

  • Drugs Antithrombin alfa (Primary)
  • Indications Blood coagulation disorders; Embolism and thrombosis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 12 Jan 2015 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
    • 21 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top